Welcome to our dedicated page for Bio-Key Intl SEC filings (Ticker: BKYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to connect BIO-key鈥檚 fingerprint technology buzz with concrete numbers? Each BIO-key International SEC filing hides vital clues鈥攆rom government contract wins to PortalGuard license renewals鈥攂ut the language can be as technical as the biometrics it describes.
Stock Titan solves that problem in seconds. Our AI-powered summaries pull plain-English insights from every 10-K and 10-Q, so the next time you search for 鈥淏IO-key quarterly earnings report 10-Q filing鈥� or wonder how R&D spending impacts margins, the answers appear before you even open the PDF. Need real-time alerts on 鈥淏IO-key insider trading Form 4 transactions鈥� or 鈥淏IO-key executive stock transactions Form 4鈥�? We stream them the moment they hit EDGAR, complete with context on historical buying patterns.
All major forms are covered:
- 10-K annual report鈥攐ur AI spots biometric revenue trends, making 鈥淏IO-key annual report 10-K simplified鈥� more than a promise.
- 10-Q quarterly updates鈥攖rack segment growth without wading through accounting jargon.
- 8-K current reports鈥攇et 鈥淏IO-key 8-K material events explained鈥� when new cybersecurity contracts close.
- DEF 14A proxy鈥攓uickly see 鈥淏IO-key proxy statement executive compensation鈥� details.
Investors use these insights to compare license versus hardware sales, monitor insider confidence, and gauge cash needs for future biometric R&D. Whether you type 鈥渦nderstanding BIO-key SEC documents with AI鈥� or ask, 鈥渨here do I find BIO-key earnings report filing analysis,鈥� this page answers instantly鈥攏o scrolling, no spreadsheets, just clarity.
BIO-key International, Inc. (BKYI) reported mixed quarterly results with revenue growth but continued losses and a going-concern qualification. For the three months ended June 30, 2025, total revenue was $1,696,907, up from $1,141,286 a year earlier, driven by higher hardware sales and modest license and services growth. Gross profit improved to $1,232,727. The company recorded a net loss of $1,167,396 for the quarter (basic and diluted loss per share $0.20) and a six-month net loss of $1,903,941.
Liquidity changed materially: cash and cash equivalents rose to $2,275,344 from $437,604 at year-end, largely from warrant exercises that generated gross proceeds of approximately $3.8 million and $3,493,505 of net financing cash. Working capital was about $503,000. Management discloses substantial doubt about the company's ability to continue as a going concern without additional financing. Major customer concentration remains (two customers represented 47% of quarterly revenue) and inventory includes a large reserve against finished goods related to delayed projects.
BIO-key International held its Annual Meeting on August 8, 2025 where shareholders elected five directors 鈥� Michael W. DePasquale, Wong Kwok Fong (Kelvin), Robert J. Michel, Emmanuel Alia and Cameron E. Williams 鈥� each receiving between 995,776 and 1,001,229 votes in favor, with 2,713,111 broker non-votes recorded on those elections.
Shareholders also ratified Bush & Associates CPA LLC as the company鈥檚 independent registered public accounting firm (3,500,203 for; 461,100 against; 52,205 abstain), approved the advisory vote on executive compensation (975,360 for; 317,871 against; 7,166 abstain; 2,713,111 broker non-votes), and approved amendments to the 2023 Stock Incentive Plan and the 2021 Employee Stock Purchase Plan with vote totals reported.
BIO-key International, Inc. (BKYI) filed its Definitive Proxy Statement (DEF 14A) for the 2025 Annual Meeting of Stockholders, scheduled for August 8 2025 at 10:00 a.m. (ET) at the company鈥檚 Holmdel, NJ headquarters. The record date is June 20 2025, when 6,848,775 common shares were outstanding, with each share entitled to one vote and no cumulative voting rights.
Shareholders will vote on six proposals: (1) election of five directors to serve until the 2026 meeting; (2) ratification of Bush & Associates CPA LLC as independent registered public accounting firm for FY 2025; (3) an advisory 鈥渟ay-on-pay鈥� vote on executive compensation; (4) an amendment to the 2023 Stock Incentive Plan; (5) an amendment to the 2021 Employee Stock Purchase Plan; and (6) other routine business. Boxes for a preliminary proxy, confidential treatment, additional materials, and soliciting material are all unchecked, confirming that this filing is the definitive statement.
The proxy materials, together with the company鈥檚 Form 10-K for the year ended December 31 2024, were first mailed on or about June 27 2025. Registered shareholders may vote in person, by mail, telephone, or internet; beneficial owners must follow their broker鈥檚 instructions. Brokers lack discretionary authority to vote uninstructed shares on Proposals 1, 3, 4, or 5, potentially resulting in broker non-votes for those items.
The filing includes a detailed table of contents covering governance, principal stockholders, executive and director compensation, and full text of the amended stock plans (Appendices A & B). No filing fee was required. Aside from the requested plan amendments, the proxy does not disclose new financial metrics, acquisitions, or other extraordinary actions.
FAQ
What is the current stock price of Bio-Key Intl (BKYI)?
What is the market cap of Bio-Key Intl (BKYI)?
